

14th May, 2025

BSE Limited

P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Press Release and Investor Presentation – Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and year ended 31st March, 2025

Dear Sir / Madam,

Further to our intimation made earlier with regard to Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and year ended 31st March, 2025 ('Financial Results'), please find enclosed herewith the Press Release and the Investor Presentation on the Financial Results.

The above information is also available on the website of the Company at www.piramalpharma.com

You are requested to kindly take the above information on record.

Yours faithfully,
For **Piramal Pharma Limited**

Tanya Sanish
Company Secretary

Encl.: a/a

Piramal Pharma Limited

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India
T: +91 22 3802 3000 / 4000; Email: shareholders.ppl@piramal.com

piramalpharma.com

PRESS RELEASE

Piramal Pharma Limited Announces Results for Q4 and FY2025

Mumbai, India | May 14, 2025: Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceuticals and wellness company, today announced its standalone and consolidated results for the Fourth Quarter (Q4) and Full Year (FY) ended 31st March 2025.

Consolidated Financial Highlights

(in ₹ Crores or as stated)

Particulars	Q4FY25	Q4FY24	YoY Growth	FY25	FY24	YoY Growth
Revenue from Operations	2,754	2,552	8%	9,151	8,171	12%
CDMO	1,788	1,649	8%	5,447	4,750	15%
CHG	705	667	6%	2,633	2,449	8%
ICH	274	238	15%	1,093	985	11%
EBITDA	603	556	8%	1,580	1,372	15%
EBITDA Margin	22%	22%		17%	17%	
PAT (before exceptional item)	154	132	16%	91	81	13%
Exceptional Item*	-	(31)	NM	-	(63)	NM
PAT (after exceptional item)	154	101	52%	91	18	411%

* Q4FY24 - ₹ 31 Cr towards non-cash write down of investment and license rights in relation to a certain third-party product no longer being commercialized; Q3FY24 - ₹ 32 Cr. related to non-recurring charges towards product recall triggered by a 3rd party supplier

Key Highlights for Q4FY25/FY25

- **Revenue from Operations** grew by 8% YoY and 12% YoY in Q4FY25 and FY25 respectively, driven primarily by CDMO business especially from on-patent commercial manufacturing
- **EBITDA** grew by 8% YoY and 15% YoY in Q4FY25 and FY25 respectively, on account of operating leverage, cost optimization, and operational excellence initiatives
- **Net-Debt to EBITDA** ratio improved to 2.7x Vs. 5.6x in FY23
- **Best-in-Class Quality Track Record** – Continue to maintain our ‘Zero OAls’ status since 2011
- **Sustainability Efforts Yielding Results** – Significant enhancement in S&P Global and EcoVadis ESG scores

Nandini Piramal, Chairperson, Piramal Pharma Limited said, “FY25 has been a steady year for the company as we crossed \$1Bn in revenues with 12% YoY growth accompanied by 17% EBITDA margin and 5x increase in Net Profits, in-line with our annual guidance. We also managed to maintain our Net Debt / EBITDA level below 3x, while making regular investments in capabilities and capacities for future growth. During the year, we progressed well on our key performance metrics such as growth in innovation related work and differentiated capabilities in the CDMO business, maintaining our leading position in inhalation anesthetic Sevoflurane in the US market, and healthy growth in our power brands in our consumer healthcare business.

We believe, we are on track to deliver on our FY2030 aspirations of becoming a \$2bn revenue company with 25% EBITDA margins and high teens ROCE.”

Key Business Highlights for Q4 and FY2025

Contract Development and Manufacturing Organization (CDMO):

- **Increasing contribution from Innovation¹ related work** - Up from 50% in FY24 to 54% in FY25, driven by commercial manufacturing of on-patent molecules
- **Robust growth in on-patent commercial manufacturing revenues** - Grew by over 50% YoY to reach \$179mn (Vs. \$116mn in FY24 and \$53mn in FY23)
- Revenues from **differentiated offerings** grew 28% YoY, contributing to 49% of CDMO revenues
- Healthy growth in **API generics business**
- **YoY improvement in EBITDA margin** driven by better procurement strategies, cost optimization and operational excellence initiatives
- **Maintained our best-in-class quality track record** - Successfully cleared 36 regulatory inspections and 165 customer audits in FY25 without any major observations

Complex Hospital Generics (CHG):

- **Inhalation Anesthesia (IA)** - Major GPO contract renewal and order wins supporting IA sales in the US. Witnessing encouraging traction in the RoW markets
- **Capacity expansion** in India completed and commercialized on time; poised to capitalize on ~US\$400 mn² Sevoflurane market opportunity in the RoW markets
- **Maintained our #1 Rank** in the US in Sevoflurane (44% market share²) and in intrathecal Baclofen (75% market share²)
- Received **approval for Neoatrimon^{®3}** for multiple markets in EU and UK by our partner BrePco Pharma. Neoatrimon[®] is the only pre-diluted, age-appropriate formulation of dopamine, approved for treating children and infants
- Moderation in EBITDA margins due to some non-recurring expenses and capacity expansion in India. However, recovery expected from FY26 with commercialization of these added capacities

India Consumer Healthcare (ICH):

- ICH business crossed the **strategic revenue milestone of ₹ 1,000 crores** during the year
- **Power Brands** continue to grow strength to strength with 20% YoY during FY25. Power Brands contributed to 49% of total ICH sales
 - o Excluding i-range, which was impacted by regulatory price control, growth in power brands was about 26% in FY25
- **New Product Launches** - Added 21 new products and 31 new SKUs in FY25
- **Investments in Media and Promotions** – 11% of ICH sales in FY25. Launched our new media campaign with Yami Gautam for Little's
- **E-commerce** sales grew at 39% YoY in FY25, contributing 21% to ICH sales,. Present on more than 20 e-commerce platforms

1. Discovery + Development + Commercial Manufacturing of products under patent; 2. As per IQVIA data, September 2024; 3. Neoatrimon[®] is developed by BrePco Biopharma; we have secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing in these regions.

Consolidated Profit and Loss Statement

(in ₹ Crores or as stated)

Particulars	Quarterly			Full Year		
	Q4FY25	Q4FY24	YoY Change	FY25	FY24	YoY Change
Revenue from Operations	2,754	2,552	8%	9,151	8,171	12%
Other Income	42	26	59%	135	175	(23%)
Total Income	2,796	2,579	8%	9,286	8,347	11%
Material Cost	955	1,014	(6%)	3,232	2,954	9%
Employee Expenses	612	494	24%	2,307	2,030	14%
Other Expenses	626	514	22%	2,167	1,991	9%
EBITDA	603	556	8%	1,580	1,372	15%
Finance Cost	104	114	(9%)	422	448	(6%)
Depreciation	243	196	24%	816	741	10%
Share of net profit of associates	16	12	35%	73	59	23%
Profit Before Tax	273	258	6%	415	242	71%
Tax	119	126	(5%)	324	161	100%
Net Profit after Tax (before exceptional item)	154	132	16%	91	81	13%
Exceptional item*	-	(31)	NM	-	(63)	NM
Net Profit after Tax (after exceptional item)	154	101	52%	91	18	411%

* Q4FY24 - ₹ 31 Cr towards non-cash write down of investment and license rights in relation to a certain third-party product no longer being commercialized;
Q3FY24 - ₹ 32 Cr. related to non-recurring charges towards product recall triggered by a 3rd party supplier

Consolidated Balance Sheet

(In ₹ Crores)

Key Balance Sheet Items	As at	
	31-Mar-25	31-Mar-24
Total Equity	8,125	7,911
Net Debt	4,199	3,932
Total	12,324	11,843
Net Fixed Assets	9,110	9,106
Tangible Assets	4,534	4,250
Intangible Assets including goodwill	3,599	3,740
CWIP (including IAUD*)	977	1,116
Net Working Capital	2,798	2,339
Other Assets [#]	416	398
Total Assets	12,324	11,843

*IAUD – Intangible Assets Under Development

Other Assets include Investments and Deferred Tax Assets (Net)

Q4FY25/FY25 Earnings Conference Call

Piramal Pharma Limited will be hosting a conference call for investors / analysts on **15th May 2025 from 9:30 AM to 10:15 AM (IST) to discuss its Q4 and FY25 Results.**

The dial-in details for the call are as under:

Event	Location & Time	Telephone Number
Conference call on 15 th May, 2025	India – 09:30 AM IST	+91 22 6280 1461 / +91 22 7115 8320 (Primary Number)
		1 800 120 1221 (Toll free number)
	USA – 12:00 AM (Eastern Time – New York)	Toll free number 18667462133
	UK – 05:00 AM (London Time)	Toll free number 08081011573
	Singapore – 12:00 PM (Singapore Time)	Toll free number 8001012045
	Hong Kong – 12:00 PM (Hong Kong Time)	Toll free number 800964448
Express Join with Diamond Pass™	Please use this link for prior registration to reduce wait time at the time of joining the call – Click Here	

About Piramal Pharma Limited:

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments.

For more information, visit: [Piramal Pharma](#) | [LinkedIn](#)

* Includes one facility via PPL's minority investment in Yapan Bio.

For Investor Queries:

Gagan Borana
Investor Relations & Enterprise Risk Management
gagan.borana@piramal.com

Madhusudan Dalmia
Investor Relations
madhusudan.dalmia@piramal.com

For Media Queries:

Madiha Vahid
Lead – Media & PR
madiha.vahid@piramal.com

Q4 & FY25 Results

May 2025



Piramal Pharma Limited



Disclaimer

This presentation and the accompanying slides (the “Presentation”), which have been prepared by Piramal Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation, directly or indirectly, in any manner, or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for any securities of the Company in any jurisdiction, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever.

Except for the historical information contained herein, statements in this Presentation and any subsequent discussions, which include words or phrases such as 'will', 'aim', 'will likely result', 'would', 'believe', 'may', 'expect', 'will continue', 'anticipate', 'estimate', 'intend', 'plan', 'contemplate', 'seek to', 'future', 'objective', 'goal', 'likely', 'project', 'on-course', 'should', 'potential', 'pipeline', 'guidance', 'will pursue' 'trend line' and similar expressions or variations of such expressions may constitute 'forward-looking statements'.

Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements.

These risks and uncertainties include, but are not limited to Company's ability to successfully implement its strategy, the Company's growth and expansion plans, the performance of the Indian economy and of the economies of various international markets, obtain regulatory approvals, provisioning policies, technological changes, investment and business income, income or cash flow projections, the performance of the industry in India and world-wide, exposure to market risks as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially from results expressed in or implied by this Presentation.

Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections. Given these uncertainties and other factors, viewers of this Presentation are cautioned not to place undue reliance on these forward-looking statements. The information in this Presentation does not constitute financial advice (nor investment, tax, accounting or legal advice) and does not take into account an investor's individual investment objectives, including the merits and risks involved in an investment in the Company or its securities, or an investor's financial situation, tax position or particular needs. Past performance information in this Presentation should not be relied upon as an indication of (and is not an indicator of) future performance.

This Presentation is not a prospectus, disclosure document, a statement in lieu of a prospectus, an offering circular, an invitation or an advertisement or an offer document under the Companies Act, 2013, together with the rules and regulations made thereunder, as amended, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation, and nothing in this Presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. The Presentation has not been independently verified and any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.


The contents of this Presentation are strictly confidential and may not be copied or disseminated, reproduced, re-circulated, published, advertised or redistributed, in whole or in part, to any other person or in any media, website or otherwise in any manner without the Company's written consent.

Note: Figures in previous periods might have been regrouped or restated, wherever necessary to make them comparable to current period. For the ease of presentation, certain financial information herein has been rounded off to one decimal place or two decimal places or whole numbers, as the case may be.

FY2024 and FY2025 – Two Good Years of Significant Recovery

Revenue from Operations


(In ₹ Crore)



EBITDA & EBITDA Margin


(EBITDA: In ₹ Crore)

EBITDA Margin




Net Profit After Tax

(In ₹ Crore)



Net Debt to EBITDA




FY23 to FY25 – Two good years of all-round recovery with 14% revenue growth CAGR, over 500 bps of EBITDA margin enhancement, and significant improvement in Net Profits. Net Debt / EBITDA also improved from 5.6x in FY23 to 2.7x in FY25

Key Highlights of the Quarter – Q4FY2025

Revenue from Operations


(In ₹ Crore)



EBITDA & EBITDA Margin


(EBITDA: In ₹ Crore)

EBITDA Margin



Net Profit After Tax¹

(In ₹ Crore)



Q4FY25 – Q4 has historically been the biggest quarter for the Company. In Q4FY25, we delivered 8% revenue growth, with 22% EBITDA margin and 52% YoY growth in Net Profit After Tax

1. Q4 FY24 - Net Profit After Tax included exceptional item of ₹ 31 Crores towards non-cash write down of investment & license rights in relation to a certain third-party product no longer being commercialized.
Q4 FY25 - Depreciation and Amortization expenses includes non-cash impairment charges of ₹ 45 Crores towards certain intangible asset in the US

Key Highlights of the Year Gone By – FY2025


FY25 – A steady year with 12% revenue & 15% EBITDA growth, and over 5x YoY increase in net profit after tax

CDMO

- **Share of Innovation Related Work**
54% in FY25 Vs. 50% in FY24
- **Surge in On-patent Commercial Manufacturing** - US\$179mn in FY25 Vs. US\$116mn in FY24
- **Share of Differentiated Offerings**
49% in FY25 Vs. 44% in FY24

▲ 15%

(In ₹ Crore)




CHG

- **Maintained #1 Rank in the US**
Sevoflurane (44% Market share¹)
Baclofen (75% Market share¹)
- **Sevoflurane India Capex**
Completed and commercialized
- **Differentiated Products** - Received approval² for Neoatrimon®

▲ 8%

(In ₹ Crore)




ICH

- **Power Brands** - Delivered a healthy YoY growth of 20%
- **E-commerce Sales** – Continued momentum with 39% YoY growth and 21% contribution to ICH sales
- **New Product Launches** – 52 new products and SKUs launched in FY25

▲ 11%

(In ₹ Crore)



Global Footprint with a Diversified Revenue Base

17

Manufacturing and
development sites¹

100+

Countries with
commercial presence


~500

CDMO customers


6,000+

CHG customers
(Hospitals)

Total FY25 Revenue by Geography



Total FY25 Revenue by Segments



1. Includes one facility via PPL's minority investment in Yapan Bio



Business Wise Performance

Performance Highlights

❖ FY2025 – 15% revenue growth accompanied by EBITDA margin expansion


- **More than 50% share of Innovation¹ related work** - 54% in FY25 vs 50% in FY24, driven by commercial manufacturing of on-patent molecules
- **On-patent commercial manufacturing** revenues grew by over 50% YoY to reach US\$179mn (Vs. US\$116mn in FY24 and US\$53mn in FY23)
- **Robust growth in revenues from differentiated offerings** – 28% YoY growth, contributing to 49% of CDMO revenues
- **YoY improvement in EBITDA Margin** driven by better procurement strategies, cost optimization and operational excellence initiatives

❖ Market Outlook

- **Positive on CDMO Industry** – Growth in global pharma industry, increased propensity to outsource, and supply chain diversification to drive long term growth
- **Watchful about current macro-economic uncertainties** - Incomplete and inconsistent recovery in funding for emerging biopharma companies
- **Trade Tariff** - Our network of globally diversified facilities places us well to succeed in the widest possible range of outcomes and evolving customer geographical preferences


Revenue Growth

(In ₹ Crore)



Deep Pipeline of Development Projects across Multiple Phases

Revenue by Services




54% of revenues from **Innovation** related work (vs. 35% in FY19, CAGR 21%)

50%+ Growth in Revenues from Commercial Products Under Patent

US\$179mn


Revenue from commercial products under patent in FY25, up from US\$116mn in FY24
 Number of commercial products under patent (9 in FY19 to 18 in FY25)

Building Development Pipeline Across Clinical Phases




Diversified Blue Chip Customer Base

Customer Mix




Revenue Concentration




Long Standing Relationships with Top 20 Clients


Share of Revenue from Top 20 clients based on Tenure



High Share of Revenues from Regulated Markets




Growth in Revenue and Contribution from Differentiated Offerings




Revenue (US\$ mn) from
Differentiated Offerings

Contribution of Differentiated Offerings
to CDMO revenue



Globally Diversified Manufacturing Footprint

Total 15 Facilities



Integrated Projects

- ❖ 127+ Integrated Projects executed since inception in 2020
- ❖ 23% contribution of Integrated orders in FY25 order book


Cross Sell Opportunities

- ❖ 15 of our Top 20 customers partnering with two or more sites
- ❖ 9 of our Top 20 customers partnering with both India and overseas sites


1. There are two facilities in Ahmedabad 2. Via PPL's minority investment in Yapan Bio

Maintaining our Best-in-Class Quality Track Record

375+ Regulatory Inspections with no OAI



~130 Audits Annually by Customers



- ❖ Successfully cleared 46 US FDA inspections, 377 total regulatory inspections and 1,911 customer audits since FY2012
- ❖ Successfully cleared 36 regulatory inspections and 165 customer audits in FY25
- ❖ **No 'Official Action Indicated (OAI)' for any of our US FDA audits since 2011**

Complex Hospital Generics Business

Performance Highlights

❖ Inhalation Anesthesia

- Major GPO contract renewal and order wins supporting IA sales in the US
- **#1 Rank in Sevoflurane** in the US with 44%¹ market share
- **Setting up of Sevoflurane manufacturing lines in India** completed on time and commercialized in April 2025. Will leverage this to capitalize on IA market opportunity in the RoW markets

❖ Intrathecal Therapy - #1 Rank in Baclofen in the US with 75%¹ market share


❖ Differentiated and Specialty Products

- Investing in 505(b)(2)'s, Complex generics, Differentiated generics, Branded products to enable long term growth
- **Neoatrimon®** - Received approval for multiple markets in EU and UK by our partner BrePco Pharma

❖ EBITDA Margins – Some moderation in FY25 due to some non-recurring expenses and capacity expansion in India. However, expect recovery from FY26 with commercialization of these added capacities

Revenue Growth

(In ₹ Crore)



CHG Revenues by Product Segment and Geography

Revenue by Product Segment

% FY25 CHG Revenue

Inhalation Anesthesia (67%)



Intrathecal Therapy (15%)




Injectable Anesthesia and Pain Management (10%)



Other Speciality Products (8%)



Revenue by Geography




75% of revenues from regulated markets of US, Europe and Japan


Unlocking Sevoflurane Opportunity Across RoW Markets

Over US\$400mn Sevoflurane Market in RoW

US\$1bn Global IA Market



US\$850+ mn Global Sevoflurane Market



PPL is market leader with 44% market share

US\$400mn Market Opportunity

- PPL current market share 9%
- Commercialized Sevoflurane manufacturing lines in Digwal to serve the RoW markets

Timely Completed Capacity Expansion in India

Commenced manufacturing lines at Digwal to supplement Sevoflurane manufacturing capacity at Bethlehem (US)



Significantly increasing the KSM manufacturing capacity at Dahej to increase vertical integration



Neoatricon® - Approval for Multiple Markets in EU and UK

A Cardiovascular Drug for Neonates, Infants and Children



Currently, there are **no approved Dopamine Hydrochloride formulations** specifically indicated for use in neonates, infants, or children, with **off-label use remaining a common practice**. The approval of Neoatricon® addresses this critical gap by ensuring precise dosing, **reducing the risk of under- or overdosing, and minimizing preparation time** in neonatal and pediatric intensive care units (NICU & PICU), facilitating **faster intervention in emergency settings**.

Neoatricon®

Age-appropriate



Ready-to-use



Sterile solution



Received approval for multiple
markets in EU and UK



This milestone marks an important step for us as we expand into a new therapeutic area. Our partnership with BrePco Biopharma has allowed us to bring forward an innovation that will significantly improve health outcomes for pediatric patients.

Peter DeYoung,
CEO, Global Pharma

India Consumer Healthcare Business

Performance Highlights

- ❖ **New Product launches** - 21 new products and 31 new SKUs launched in FY25. Products launched in last 24 months contributed 8% to ICH sales



- ❖ **Power Brands grew 22%/20% YoY** during Q4FY25/FY25, contributing 49% to total ICH sales for the year

- Growth was driven by Little's, Lacto Calamine and CIR

- ❖ **Advertisement Spends in FY2025 at 11%** of ICH sales

- Launched our new media campaign with Yami Gautam for Little's. #SwitchToSofter


- ❖ **E-commerce sales grew at 41% / 39% YoY** in Q4FY25 / FY25, contributing 24% / 21% to ICH sales, respectively. Present on 20+ e-commerce platforms

Revenue Growth

(In ₹ Crore)

▲ 15%

▲ 11%



Focus on Power Brands with Brand Promotion and Marketing



Little's
Wipes, Toys, Diapers,
Feeding Range



Tetmosol
Medicated Soap,
Cream & Powder



CIR
Adult Diapers,
Bed Bath Wipes



Lacto Calamine
Oil Control Lotion,
Facewash, Sunscreen




i-range
Contraceptive Pill, Ovulation
& Pregnancy Test Kit



Polycrol
Antacid


Investments in Brand Promotion and Marketing

(In ₹ Crore)



Strong Growth in our Power Brands

(In ₹ Crore)



Multi-channel Distribution Network and Tech-enabled Sales

Presence Across Traditional And Alternate Trade Channels

Wide coverage across general trade and chemist



Presence in **~180K chemists** and **cosmetics shops**

Strengthening presence in modern trade



Presence in over **8,000 modern trade outlets**

Expanding presence on E-Commerce



Presence on over **20 leading e-commerce platforms**

Direct-to-Customer (D2C)



Own D2C website handling **over 7.5K consumer orders every month**

We have **100% tech-enabled sales coverage** and **leverage analytics** to enhance the productivity of our field force

Joint Venture Arrangement



Ownership

49%



abbvie

Ownership

51%

In FY2025, the JV reported[#] revenue of ₹493 Cr. with PAT margin of 28%

Continue to be one of the
market leaders
in the Indian
Ophthalmology segment

400+
employees including
sales force

Strong presence in
**glaucoma, dry
eye, infections
and inflammation**

Key Brands
Refresh, Ozurdex,
Combigan, Lumigan,
Alphagan, Predforte



Financials

Consolidated Financials Highlights

(in ₹ Cr. or as stated)

Particulars	Q4FY25	Q4FY24	YoY Change	FY25	FY24	YoY Change
Revenue from Operations¹	2,754	2,552	8%	9,151	8,171	12%
CDMO	1,788	1,649	8%	5,447	4,750	15%
CHG	705	667	6%	2,633	2,449	8%
ICH	274	238	15%	1,093	985	11%
EBITDA	603	556	8%	1,580	1,372	15%
EBITDA Margin	22%	22%		17%	17%	
PAT (before exceptional item)	154	132	16%	91	81	13%
Exceptional Item ²	-	(31)	NM	-	(63)	NM
PAT (after exceptional item)	154	101	52%	91	18	411%

1. Revenue from Operations includes foreign exchange gains/losses

2. Q4FY24 - ₹ 31 Cr towards non-cash write down of investment and license rights in relation to a certain third-party product no longer being commercialized;
Q3FY24 - ₹ 32 Cr. related to non-recurring charges towards product recall triggered by a 3rd party supplier

Consolidated Financials Highlights

(In ₹ Crore)

Key Balance Sheet Items	As on 31-Mar-25	As on 31-Mar-24
Total Equity	8,125	7,911
Net Debt	4,199	3,932
Total	12,324	11,843
Net Fixed Assets	9,110	9,106
Tangible Assets	4,534	4,250
Intangible Assets including goodwill	3,599	3,740
CWIP (including IAUD*)	977	1,116
Net Working Capital	2,798	2,339
Other Assets [#]	416	398
Total	12,324	11,843

*IAUD – Intangible Assets Under Development

[#] Other Assets include Investments and Deferred Tax Assets (Net)



Reiterating our FY2030 Aspirations

Financial Aspirations for FY2030

3x

Over **3x Growth** in
EBITDA



~25%
EBITDA Margins

2x


More than **Double** the
Revenues



US\$2+ Bn
Revenue

1x

Reduce Leverage
on the Balance Sheet



~1x
Net debt to EBITDA



Exponential Growth
in PAT

Early Teens PAT Margins



Enhance ROCE

High Teens ROCE

Note:- The aspirations mentioned above does not include Inorganic growth

US\$2+ Bn Company with 25% EDITDA Margin by FY2030

Strategic Goals for FY2030

US\$1.2 Bn revenues with **~25%**
EBITDA margin



Emerge as a fast-growing, **innovation**-focused **integrated** CDMO, leveraging our **scientific excellence** and our **global network** of end-to-end and **differentiated** services to bring valued solutions to our customers and their patients

US\$600 Mn revenues with **25%+**
EBITDA margin



Become a leading **critical care** company by **strengthening our core** of inhalation anesthesia, injectable pain, and intrathecal therapies and building a growing portfolio of **differentiated** and **specialty** products for patients


US\$200 Mn revenues with **double-digit**
EBITDA margin



Establish ourselves as a **significant player** in the Indian consumer healthcare segment with market **leading brands** and **extensive distribution** reach

Key Investment Highlights

US\$2+ Bn Global Pharma, Health & Wellness Company by FY2030



Dial-in Details for Q4 and FY25 Earnings Conference Call

Event	Location & Time	Telephone Number
Conference call on 15 th May, 2025	India – 09:30 AM IST	+91 22 6280 1461 / +91 22 7115 8320 (Primary Number)
		1 800 120 1221 (Toll free number)
	USA – 12:00 AM (Eastern Time – New York)	Toll free number 18667462133
	UK – 05:00 AM (London Time)	Toll free number 08081011573
	Singapore – 12:00 PM (Singapore Time)	Toll free number 8001012045
	Hong Kong – 12:00 PM (Hong Kong Time)	Toll free number 800964448
Express Join with Diamond Pass™	Please use this link for prior registration to reduce wait time at the time of joining the call – Click Here	

For Investor Queries:

Gagan Borana

Investor Relations and Enterprise Risk Management

Email: gagan.borana@piramal.com



Madhusudan Dalmia

Investor Relations

Email: madhusudan.dalmia@piramal.com



Our Websites:-

Piramal Pharma Limited

www.piramalpharma.com

Complex Hospital Generics

www.piramalcriticalcare.com

CDMO

www.piramalpharmasolutions.com

India Consumer Healthcare

www.piramalcpd.com